Screening of a chemogenetic library unveils dual-stage antiplasmodials with low cytotoxicity
Antimicrobial Agents and Chemotherapy · 04.11.2026 · 70 (11)
DOI: 10.1128/aac.01613-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.11.2026. Verfasst von Laura Torres und 14 weiteren Autor:innen. Beteiligte Einrichtung: Open Innovation at Global Health Disease Area, Biomedical Research, Novartis, Emeryville, California, USA. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium berghei, Plasmodium falciparum, Small Molecule Libraries. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The global effort to eradicate malaria requires the development of drugs with novel mechanisms of action and differentiated pharmacological profiles. Both liver and blood phases of Plasmodium infection are essential for disease progression and transmission, making them primary targets for pharmacological intervention. In this study, we established a dual-luciferase reporter assay to simultaneously assess Plasmodium berghei liver-stage development and host cell viability. Screening a library of bioactive small molecules with annotated human targets revealed several inhibitors with potent liver-stage activity and minimal cytotoxicity. Further profiling against Plasmodium falciparum asexual blood stages identified compounds with dual-stage activity, underscoring their potential utility for development as either prophylactic or therapeutic agents. Knowledge of their human targets will facilitate investigation into host- or parasite-directed antimalarial mechanisms, thereby accelerating both biological insight and rational drug development. Our findings constitute a valuable resource for research on malaria biology and the discovery of next-generation antiplasmodials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Open Innovation at Global Health Disease Area, Biomedical Research, Novartis, Emeryville, California, USA.
- Global Health Disease Area, Biomedical Research, Novartis, Emeryville, California, USA.
- Discovery Sciences, Biomedical Research, Novartis, Emeryville, California, USA.
- Global Discovery Chemistry, Biomedical Research, Novartis, Emeryville, California, USA.
- Discovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
ORCID-Profile: Srinivasa P S Rao, Anke Harupa, Gabriel Mitchell
Zitieren
APA
Torres, L., Fishbaugher, M. E., Lam, M., Chao, A. T., Martyn, C., Pei, L., Sengupta, D., Dauphinais, M., Gable, J. E., Rao, S. P. S., Renner, S., Guiguemde, W. A., Mikolajczak, S. A., Harupa, A., & Mitchell, G. (2026). Screening of a chemogenetic library unveils dual-stage antiplasmodials with low cytotoxicity. Antimicrobial Agents and Chemotherapy, 70(11). https://doi.org/10.1128/aac.01613-25
Vancouver
Torres L, Fishbaugher ME, Lam M, Chao AT, Martyn C, Pei L, et al. Screening of a chemogenetic library unveils dual-stage antiplasmodials with low cytotoxicity. Antimicrobial Agents and Chemotherapy. 2026;70(11). doi:10.1128/aac.01613-25
BibTeX
@article{Torres2026,
author = {Torres, Laura and Fishbaugher, Matthew E and Lam, Melanie and Chao, Alexander T and Martyn, Calla and Pei, Luying and Sengupta, Debapriya and Dauphinais, Maxime and Gable, Jonathan E and Rao, Srinivasa P S and Renner, Steffen and Guiguemde, W Armand and Mikolajczak, Sebastian A and Harupa, Anke and Mitchell, Gabriel},
title = {Screening of a chemogenetic library unveils dual-stage antiplasmodials with low cytotoxicity},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {11},
doi = {10.1128/aac.01613-25}
}
EUVIMED